- Datum13.03.2025
- Uhrzeit08:00 - 17:00 Uhr
- Veranstalter
stock3
3SBio Inc. Aktie
Verkaufen
Kaufen
3SBio Inc. Chart
3SBio Inc. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (L&S)
5,64 %
Intraday
18,39 %
1 Woche
33,77 %
1 Monat
42,07 %
Seit Jahresbeginn
73,11 %
1 Jahr
60,19 %
3 Jahre
14,44 %
5 Jahre
Wikifolio
Passender Service zu 3SBio Inc.
Webinar zu 3SBio Inc.
Kursinformationen (L&S)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)0,580-1,070
- Jahrestief / Hoch (€)0,680-1,070
- Schlusskurs (Vortag)
- Eröffnungskurs
Wichtigste Eigenschaften
Dividenden von 3SBio Inc.
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2026 (e) | ||
| - | 2025 (e) | ||
| - | 2024 (e) | ||
| 27.06.2022 | 2021 | 0,20 $ | 3,04 % |
| 29.06.2018 | 2017 | 0,0685 $ | 0,41 % |
Termine von 3SBio Inc.
- Mär253SBio Inc.Q4 2024 Earnings Release
- Aug203SBio Inc.Q2 2025 Earnings Release
- Mär313SBio Inc.Q4 2025 Earnings Release
Beschreibung
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
